Eurofins Reinforces Its Agroscience Contract Research Services by Acquiring SGS’ Crop Science Operations
December 18 2023 - 12:45AM
Business Wire
Regulatory News:
Eurofins Scientific (EUFI.PA) (Paris:ERF), a global leader in
agroscience contract research services, announces the signing of an
agreement to acquire the operations of SGS Crop Science in 14
countries. The business generated revenues of approximately CHF 46m
in 2022. The transaction is subject to consultation with SGS Crop
Science’s local stakeholders as required by the local jurisdictions
and is expected to close in the coming months.
Consisting of more than 480 employees and locations in Europe,
North America, South Africa and Brazil, SGS Crop Science is
composed of activities in Agroscience Contract Research,
Agricultural Input Testing and Precision Farming & Agronomy
services. Its addition complements Eurofins’ Agroscience Services
and Agro Testing businesses and its vision to be a global,
high-quality and ‘one-stop’ provider of services to screen and
develop, register and steward new and existing seeds and
agrochemicals for its clients in the agrosciences and agro testing
industries as well as supporting industrial chemicals clients with
data generation for REACH filings and farmers, agronomist or
sample-taking companies with value-added (soil) testing.
Comment from Dr Gilles Martin, Eurofins CEO: “We are very
pleased to welcome SGS Crop Science’s teams to Eurofins. The
acquisition further reinforces Eurofins’ service offering in
agroscience contract research services and agro testing as well as
its commitment to providing the best possible standard of
scientific and regulatory support to its clients.”
Notes to Editors:
For more information, please visit www.eurofins.com
About Eurofins – the global leader in
bio-analysis
Eurofins is Testing for Life. The Eurofins network of companies
believes that it is a global leader in food, environment,
pharmaceutical and cosmetic product testing and in discovery
pharmacology, forensics, advanced material sciences and agroscience
contract research services. It is also one of the market leaders in
certain testing and laboratory services for genomics, and in the
support of clinical studies, as well as in biopharma contract
development and manufacturing. It also has a rapidly developing
presence in highly specialised and molecular clinical diagnostic
testing and in-vitro diagnostic products.
With over 61,000 staff across a decentralised and
entrepreneurial network of ca. 900 laboratories in 61 countries,
Eurofins offers a portfolio of over 200,000 analytical methods to
evaluate the safety, identity, composition, authenticity, origin,
traceability and purity of a wide range of products, as well as
providing innovative clinical diagnostic testing services and
in-vitro diagnostic products.
Eurofins companies’ broad range of services are important for
the health and safety of people and our planet. The ongoing
investment to become fully digital and maintain the best network of
state-of-the-art laboratories and equipment supports our objective
to provide our customers with high-quality services, innovative
solutions and accurate results in the best possible turnaround time
(TAT). Eurofins companies are well positioned to support clients’
increasingly stringent quality and safety standards and the
increasing demands of regulatory authorities as well as the
evolving requirements of healthcare practitioners around the
world.
Eurofins has grown very strongly since its inception and its
strategy is to continue expanding its technology portfolio and its
geographic reach. Through R&D and acquisitions, the Group draws
on the latest developments in the field of biotechnology and
analytical chemistry to offer its clients unique analytical
solutions.
Shares in Eurofins Scientific are listed on the Euronext Paris
Stock Exchange (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg ERF
FP).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231217729439/en/
Investor Relations Eurofins Scientific SE Phone: +32 2 766 1620
E-mail: ir@eurofins.com
Enerplus (NYSE:ERF)
Historical Stock Chart
From Apr 2024 to May 2024
Enerplus (NYSE:ERF)
Historical Stock Chart
From May 2023 to May 2024